Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumi-NHL: AZD4512 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
jRCT2031250366Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of AZD4512 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 5 more, sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities (DLTs), Treatment-emergent and treatment-related adverse events and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
AZD4512
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on jRCT2031250366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250366.